Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(50%)
Terminated
1(25%)

Phase Distribution

Ph phase_4
1
25%
Ph phase_2
1
25%
Ph phase_3
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(2)

Detailed Status

Recruiting2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

recruiting250%
withdrawn125%
terminated125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

NCT04375800
recruitingphase_3

DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

NCT07075146
terminatedphase_4

Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

NCT04665375
withdrawnphase_3

Doravirine and Weight Gain in Antiretroviral Naive

NCT05457530

Clinical Trials (4)

Showing 4 of 4 trials
NCT04375800Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Recruiting
NCT07075146Phase 3

DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity

Recruiting
NCT04665375Phase 4

Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?

Terminated
NCT05457530Phase 3

Doravirine and Weight Gain in Antiretroviral Naive

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4